PDEX vs. NVNO, MGRM, SEPA, STIM, HSAQ, NSPR, DRIO, ICCM, AMIX, and APYX
Should you be buying Pro-Dex stock or one of its competitors? The main competitors of Pro-Dex include enVVeno Medical (NVNO), Monogram Orthopaedics (MGRM), SEP Acquisition (SEPA), Neuronetics (STIM), Health Sciences Acquisitions Co. 2 (HSAQ), InspireMD (NSPR), DarioHealth (DRIO), IceCure Medical (ICCM), Autonomix Medical (AMIX), and Apyx Medical (APYX). These companies are all part of the "surgical & medical instruments" industry.
Pro-Dex (NASDAQ:PDEX) and enVVeno Medical (NASDAQ:NVNO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, community ranking, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.
Pro-Dex has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, enVVeno Medical has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500.
enVVeno Medical received 10 more outperform votes than Pro-Dex when rated by MarketBeat users. Likewise, 62.65% of users gave enVVeno Medical an outperform vote while only 60.58% of users gave Pro-Dex an outperform vote.
15.3% of Pro-Dex shares are held by institutional investors. Comparatively, 34.7% of enVVeno Medical shares are held by institutional investors. 42.6% of Pro-Dex shares are held by company insiders. Comparatively, 17.0% of enVVeno Medical shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, enVVeno Medical had 1 more articles in the media than Pro-Dex. MarketBeat recorded 1 mentions for enVVeno Medical and 0 mentions for Pro-Dex. Pro-Dex's average media sentiment score of 1.91 beat enVVeno Medical's score of 0.00 indicating that Pro-Dex is being referred to more favorably in the media.
Pro-Dex has a net margin of 4.13% compared to enVVeno Medical's net margin of 0.00%. Pro-Dex's return on equity of 6.50% beat enVVeno Medical's return on equity.
Pro-Dex has higher revenue and earnings than enVVeno Medical. enVVeno Medical is trading at a lower price-to-earnings ratio than Pro-Dex, indicating that it is currently the more affordable of the two stocks.
Summary
Pro-Dex beats enVVeno Medical on 9 of the 14 factors compared between the two stocks.
Get Pro-Dex News Delivered to You Automatically
Sign up to receive the latest news and ratings for PDEX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PDEX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
